AIM ImmunoTech's Stock Falls 50% Following $8M Securities Offering

AIM ImmunoTech's stock price dropped by 50% after the company announced a public offering of 2 million shares of common stock, Class E warrants to purchase up to 2 million shares of common stock, and Class F warrants to purchase up to 2 million shares of common stock. The offering aims to raise $8 million.

AIM ImmunoTech (AIM) stock experienced a significant drop of 51.39% in pre-market trading on Tuesday, following the announcement of a public offering. The company is set to sell 2 million shares of common stock at $4 each, along with Class E and Class F warrants to purchase an additional 2 million shares each [1].

The offering, which aims to raise approximately $8 million in gross proceeds, includes Class E warrants that expire in five years and Class F warrants that expire in 18 months, both exercisable immediately upon issuance at an exercise price of $4 per share [2][3].

The stock's decline can be attributed to the dilution of existing shareholders' ownership stakes, as the offering price of $4 is well below the shares' prior closing price of $7.20. Additionally, the public offering is expected to close around July 30, 2025, subject to customary closing conditions [2][3].

Wall Street coverage of AIM ImmunoTech is thin, but TipRanks' AI analyst Spark rates the stock a Neutral (44) with an $8.50 price target, representing a potential 18.06% upside [1].

References:

[1] https://www.tipranks.com/news/why-is-aim-immunotech-stock-aim-down-50-today
[2] https://au.investing.com/news/stock-market-news/aim-immunotech-stock-plunges-after-pricing-8-million-public-offering-93CH-3947920
[3] https://www.investing.com/news/stock-market-news/aim-immunotech-stock-plunges-after-pricing-8-million-public-offering-93CH-4157977